India Technical Panel Rejects Trials Of 19 Of 47 Drugs Reviewed
This article was originally published in PharmAsia News
Executive Summary
India's new panel for regulating clinical trials has recommended rejection of 19 of the first 47 new proposals it reviewed, including those of drug giants Novartis and Roche and local firms Cadila and Wockhardt.